Resistance to therapy in BRCA2 mutant cells due to loss of the nucleosome remodeling factor CHD4

Hereditary cancers derive from gene defects that often compromise DNA repair. Thus, BRCA-associated cancers are sensitive to DNA-damaging agents such as cisplatin. The efficacy of cisplatin is limited, however, by the development of resistance. One cisplatin resistance mechanism is restoration of ho...

Descripción completa

Detalles Bibliográficos
Autores principales: Guillemette, Shawna, Serra, Ryan W., Peng, Min, Hayes, Janelle A., Konstantinopoulos, Panagiotis A., Green, Michael R., Cantor, Sharon B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory Press 2015
Materias:
Research Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4358401/
https://www.ncbi.nlm.nih.gov/pubmed/25737278
http://dx.doi.org/10.1101/gad.256214.114

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4358401/
https://www.ncbi.nlm.nih.gov/pubmed/25737278
http://dx.doi.org/10.1101/gad.256214.114

Ejemplares similares